Peter J. Reddig

Array ( [id] => 16222751 [patent_doc_number] => 20200247867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => CHIMERIC ANTIGEN RECEPTORS (CAR) TO SELECTIVELY TARGET PROTEIN COMPLEXES [patent_app_type] => utility [patent_app_number] => 16/744598 [patent_app_country] => US [patent_app_date] => 2020-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10876 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16744598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376386 [patent_doc_number] => 20200325228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/742657 [patent_app_country] => US [patent_app_date] => 2020-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16742657 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15960887 [patent_doc_number] => 20200164195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => METHODS FOR CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 16/716102 [patent_app_country] => US [patent_app_date] => 2019-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16716102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398793 [patent_doc_number] => 20200339651 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => METHODS FOR B CELL PRECONDITIONING IN CAR THERAPY [patent_app_type] => utility [patent_app_number] => 16/708397 [patent_app_country] => US [patent_app_date] => 2019-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 86641 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16708397 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18134774 [patent_doc_number] => 11560427 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-24 [patent_title] => Heavy-chain antibodies (VHHs) against claudin 18A2 and use thereof [patent_app_type] => utility [patent_app_number] => 17/422204 [patent_app_country] => US [patent_app_date] => 2019-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 12 [patent_no_of_words] => 15961 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17422204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012811 [patent_doc_number] => 20200181248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => ANTIBODY AGAINST SECRETED N-TERMINAL PEPTIDE OF GPC3 PRESENT IN BLOOD OR C-TERMINAL PEPTIDE OF GPC3 [patent_app_type] => utility [patent_app_number] => 16/700416 [patent_app_country] => US [patent_app_date] => 2019-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14892 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700416 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16445103 [patent_doc_number] => 10837019 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-17 [patent_title] => Chimeric antigen receptors targeting B-cell maturation antigen [patent_app_type] => utility [patent_app_number] => 16/684978 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 39 [patent_no_of_words] => 14310 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15590351 [patent_doc_number] => 20200071710 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/684994 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14221 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684994 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15650281 [patent_doc_number] => 20200087670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/684962 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15590347 [patent_doc_number] => 20200071708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/683543 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15590345 [patent_doc_number] => 20200071707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/683524 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14220 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15650279 [patent_doc_number] => 20200087669 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/683625 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15650275 [patent_doc_number] => 20200087667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/683477 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14222 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683477 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15590343 [patent_doc_number] => 20200071706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/683453 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14221 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15556861 [patent_doc_number] => 20200062842 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => ANTIBODIES DIRECTED AGAINST SIGNAL PEPTIDES, METHODS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/683497 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16733 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15590341 [patent_doc_number] => 20200071705 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/683435 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14219 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683435 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15650277 [patent_doc_number] => 20200087668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/683494 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14230 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15711603 [patent_doc_number] => 20200102567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/683417 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868488 [patent_doc_number] => 20210161955 [patent_country] => US [patent_kind] => A2 [patent_issue_date] => 2021-06-03 [patent_title] => COMPOSITIONS CONTAINING A CELL PRODUCT COMPRISING AN EXPANDED AND ENRICHED POPULATION OF SUPERACTIVATED CYTOKINE KILLER T CELLS AND METHODS FOR MAKING SAME [patent_app_type] => utility [patent_app_number] => 16/682422 [patent_app_country] => US [patent_app_date] => 2019-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38784 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16682422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868488 [patent_doc_number] => 20210161955 [patent_country] => US [patent_kind] => A2 [patent_issue_date] => 2021-06-03 [patent_title] => COMPOSITIONS CONTAINING A CELL PRODUCT COMPRISING AN EXPANDED AND ENRICHED POPULATION OF SUPERACTIVATED CYTOKINE KILLER T CELLS AND METHODS FOR MAKING SAME [patent_app_type] => utility [patent_app_number] => 16/682422 [patent_app_country] => US [patent_app_date] => 2019-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38784 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16682422 [rel_patent_id] =>[rel_patent_doc_number] =>)